Society Helps Fund 'ChariotMS' Clinical Trial in U.K. for People With Advanced MS
November 20, 2020
November 20, 2020
NEW YORK, Nov. 20 -- The National Multiple Sclerosis Society issued the following news:
One of the first multiple sclerosis clinical trials to focus on people who walk with difficulty, or not at all, is about to begin in the United Kingdom. The ChariotMS trial will test whether cladribine tablets (Mavenclad(R)) can slow the progression of upper limb disability in people with advanced MS, who are rarely included in clinical trials. Mavenclad is an approved therapy for highly active r . . .
One of the first multiple sclerosis clinical trials to focus on people who walk with difficulty, or not at all, is about to begin in the United Kingdom. The ChariotMS trial will test whether cladribine tablets (Mavenclad(R)) can slow the progression of upper limb disability in people with advanced MS, who are rarely included in clinical trials. Mavenclad is an approved therapy for highly active r . . .